Stock listing
Munich:1HM Adaptive Biotechnologies Corporation Aktie
German listing (Munich) of Adaptive Biotechnologies Corporation · home listing NASDAQ:ADPT
Follow Adaptive Biotechnologies Corporation into a list and get an email when it puts out news.
Share price · MUN:1HM
€25.79 EUR 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- €25.79 – €25.79 EURNov 20, 2026
- Market cap
- €4.12B EURAt the close on Nov 20, 2026 · price × 159.6M shares outstanding
- 52-week range
- €10.92 – €26.27 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €72 EURMedian day 0 shares · 54 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ADPT · Home | $27.93 USD | -0.53 (-1.9%) | 2,483,129 | $27.43 | $28.23 | $27.15 | $28.46 | Close on Nov 20, 2026 |
| Dusseldorf:1HM | €25.07 EUR | -0.61 (-2.4%) | — | €25.07 | €25.07 | €25.07 | €25.68 | Close on Nov 20, 2026 |
| Frankfurt:1HM | €25.74 EUR | +0.16 (+0.6%) | — | €25.74 | €25.74 | €25.74 | €25.58 | Close on Nov 19, 2026 |
| Munich:1HM | €25.79 EUR | 0.00 (0.0%) | — | €25.79 | €25.79 | €25.79 | €25.79 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · MUN:1HM · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €23.68 | -0.231 | -1.0% | €23.68 | €23.68 | €23.68 | 0 | |
| €23.91 | +1.276 | +5.6% | €23.91 | €23.91 | €23.91 | 0 | |
| €22.63 | +0.001 | 0.0% | €22.63 | €22.63 | €22.63 | 0 | |
| €22.63 | -1.72 | -7.1% | €22.63 | €22.63 | €22.63 | 0 | |
| €24.35 | -0.499 | -2.0% | €24.35 | €24.35 | €24.35 | 0 | |
| €24.85 | +0.086 | +0.3% | €24.85 | €24.85 | €24.85 | 0 | |
| €24.77 | +0.181 | +0.7% | €24.97 | €25.24 | €24.63 | 33 | |
| €24.59 | +1.341 | +5.8% | €24.59 | €24.59 | €24.59 | 0 | |
| €23.24 | +0.797 | +3.6% | €23.24 | €23.24 | €23.24 | 0 | |
| €22.45 | +0.359 | +1.6% | €22.45 | €22.45 | €22.45 | 0 | |
| €22.09 | -0.008 | 0.0% | €22.09 | €22.09 | €22.09 | 0 | |
| €22.10 | +0.614 | +2.9% | €22.10 | €22.10 | €22.10 | 0 | |
| €21.48 | +0.153 | +0.7% | €21.48 | €21.48 | €21.48 | 0 | |
| €21.33 | -0.151 | -0.7% | €21.33 | €21.33 | €21.33 | 0 | |
| €21.48 | -1.343 | -5.9% | €21.60 | €21.66 | €21.46 | 143 | |
| €22.82 | -0.135 | -0.6% | €22.82 | €22.82 | €22.82 | 0 | |
| €22.96 | +0.12 | +0.5% | €22.96 | €22.96 | €22.96 | 0 | |
| €22.84 | -0.354 | -1.5% | €22.84 | €22.84 | €22.84 | 0 | |
| €23.19 | -0.376 | -1.6% | €23.19 | €23.19 | €23.19 | 0 | |
| €23.57 | +0.195 | +0.8% | €23.57 | €23.57 | €23.57 | 0 | |
| €23.37 | -0.492 | -2.1% | €23.37 | €23.37 | €23.37 | 0 | |
| €23.87 | -0.222 | -0.9% | €23.87 | €23.87 | €23.87 | 0 | |
| €24.09 | -2.178 | -8.3% | €24.09 | €24.09 | €24.09 | 0 | |
| €26.27 | +1.333 | +5.3% | €26.27 | €26.27 | €26.27 | 0 | |
| €24.93 | +0.216 | +0.9% | €24.93 | €24.93 | €24.93 | 0 | |
| €24.72 | -0.654 | -2.6% | €24.72 | €24.72 | €24.72 | 0 | |
| €25.37 | +0.06 | +0.2% | €25.37 | €25.37 | €25.37 | 0 | |
| €25.31 | -0.071 | -0.3% | €25.31 | €25.31 | €25.31 | 0 | |
| €25.38 | -0.147 | -0.6% | €25.38 | €25.38 | €25.38 | 0 | |
| €25.53 | +0.042 | +0.2% | €25.53 | €25.53 | €25.53 | 0 | |
| €25.49 | +0.853 | +3.5% | €25.49 | €25.49 | €25.49 | 0 | |
| €24.63 | -0.177 | -0.7% | €24.63 | €24.63 | €24.63 | 0 | |
| €24.81 | +0.274 | +1.1% | €24.81 | €24.81 | €24.81 | 0 | |
| €24.54 | -0.222 | -0.9% | €24.54 | €24.54 | €24.54 | 0 | |
| €24.76 | +0.22 | +0.9% | €24.76 | €24.76 | €24.76 | 0 | |
| €24.54 | +0.47 | +2.0% | €24.54 | €24.54 | €24.54 | 0 | |
| €24.07 | +1.38 | +6.1% | €24.07 | €24.07 | €24.07 | 0 | |
| €22.69 | +1.731 | +8.3% | €22.69 | €22.69 | €22.69 | 0 | |
| €20.96 | +0.148 | +0.7% | €20.96 | €20.96 | €20.96 | 0 | |
| €20.81 | -0.084 | -0.4% | €21.01 | €21.04 | €20.79 | 10 | |
| €20.89 | -0.166 | -0.8% | €20.89 | €20.89 | €20.89 | 0 | |
| €21.06 | +0.058 | +0.3% | €21.06 | €21.06 | €21.06 | 0 | |
| €21.00 | -0.056 | -0.3% | €21.00 | €21.00 | €21.00 | 0 | |
| €21.06 | -0.184 | -0.9% | €21.06 | €21.06 | €21.06 | 0 | |
| €21.24 | +0.088 | +0.4% | €21.24 | €21.24 | €21.24 | 0 | |
| €21.15 | +0.002 | 0.0% | €21.15 | €21.15 | €21.15 | 0 | |
| €21.15 | -0.095 | -0.4% | €21.15 | €21.15 | €21.15 | 0 | |
| €21.25 | -0.483 | -2.2% | €21.25 | €21.25 | €21.25 | 0 | |
| €21.73 | -0.267 | -1.2% | €21.73 | €21.73 | €21.73 | 0 | |
| €22.00 | -0.314 | -1.4% | €22.00 | €22.00 | €22.00 | 0 | |
| €22.31 | +0.326 | +1.5% | €22.31 | €22.31 | €22.31 | 0 | |
| €21.98 | -0.268 | -1.2% | €21.98 | €21.98 | €21.98 | 0 | |
| €22.25 | +0.341 | +1.6% | €22.25 | €22.25 | €22.25 | 0 | |
| €21.91 | -0.047 | -0.2% | €21.91 | €21.91 | €21.91 | 0 | |
| €21.96 | +0.64 | +3.0% | €21.96 | €21.96 | €21.96 | 0 | |
| €21.32 | -0.226 | -1.0% | €21.32 | €21.32 | €21.32 | 0 | |
| €21.54 | +0.129 | +0.6% | €21.54 | €21.54 | €21.54 | 0 |
Splits
1 split · MUN:1HM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation |
- Ticker
- Munich:1HM
- Asset type
- Stock
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Nov 18, 2026
Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
Latest earnings call · Nov 4, 2026
Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · May 5, 2026
Q1 2026 Earnings Presentation
Earnings · 31 slides
Latest news
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Nov 4, 2026
Closed €23.91 (+5.6%) on Nov 5, 2026
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
Oct 14, 2026
Closed €22.96 (+0.5%) on Oct 15, 2026
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Sep 25, 2026
Closed €25.49 (+3.5%) on Sep 25, 2026
Adaptive Biotechnologies Announces Update to NCCN Guidelines for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ
Sep 18, 2026
Closed €24.54 (+2.0%) on Sep 18, 2026
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 1, 2026
Closed €21.25 (-2.2%) on Sep 2, 2026
Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
Aug 4, 2026
Closed €20.97 (+5.1%) on Aug 5, 2026
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
Jul 29, 2026
Closed €19.57 (+0.4%) on Jul 30, 2026
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
Jul 9, 2026
Closed €18.68 (+3.2%) on Jul 10, 2026
Adaptive Biotechnologies Corporation on 6ix
- News releases
- 32 in the last 12 months · 181 in all · newest Nov 18, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Nov 4, 2026
- Decks
- 32 decks · latest May 5, 2026
Where Adaptive Biotechnologies Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ADPT · Home listing | NASDAQ | United States | USD |
| gettex:1HM | gettex | Germany | EUR |
| LS Exchange:A2PLR5 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PLR5 | Lang & Schwarz | Germany | EUR |
| Tradegate:1HM | Tradegate | Germany | EUR |
| BOATS:ADPT | BOATS | United States | USD |
| Dusseldorf:1HM | Dusseldorf | Germany | EUR |
| Frankfurt:1HM | Frankfurt | Germany | EUR |
| Hamburg:1HM | Hamburg | Germany | EUR |
| Munich:1HM · This page | Munich | Germany | EUR |
| Stuttgart:1HM | Stuttgart | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.22B USD
- P/E
- Loss
- EV/sales
- 14.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 25.7×
- Gross margin
- 74.0%
- Operating margin
- −16.2%
- Net margin
- −23.7%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.39
Forecasts
6 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 32.57 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.37 · 1 analyst
- Revenue, year to Dec 2026
- 307M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Chad Robins | Chief Executive Officer, Co-founder, Chairman of the Board |
| Kyle Piskel | Chief Financial Officer |
| Julie Rubinstein | President & Chief Operating Officer |
| ADAPTIVE INVESTORSKarina Calzadilla | Vice President, Investor Relations and FP& |
| ADAPTIVE MEDIAErica Jones | Associate Corporate Communications |
| Erica Jones | Associate Corporate Communications Director |
| Karina Calzadilla | Vice President, Investor Relations and FP&A |
| Clarice McCauley | VP, Head of Legal |
| Mary Pat Lancelotta | Senior Vice President, Global Market and Business Development |
| Francis Lo | Chief People Officer |
| Sharon Benzeno | Chief Commercial Officer, Immune Medicine |
| Susan Bobulsky | Chief Commercial Officer, MRD |
Board
| Director | Role |
|---|---|
| Chad Robins | Chief Executive Officer, Co-founder, Chairman of the Board |
| Katey Owen | Board Member |
| Michelle Griffin | Board Member |
| Peter Neupert | Board Member |
| Robert Hershberg | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 4:30 PM ET | Replay |
| Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2026 Earnings Call | Wed, Jul 29, 2026 · 4:30 PM ET | Replay |
| Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2026 Earnings Call | Tue, May 05, 2026 · 4:30 PM ET | Replay |
| Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2025 Earnings Call | Thu, Feb 05, 2026 · 7:30 PM ET | Replay |
| Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 4:30 PM ET | Replay |
| Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2025 Earnings Call | Thu, May 01, 2025 · 4:30 PM ET | Replay |
| Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2024 Earnings Call | Tue, Feb 11, 2025 · 4:30 PM ET | Replay |
| Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 4:30 PM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | +0.5% |
| Q2 2026 | Jul 29, 2026 · After close | +7.2% |
| Q1 2026 | May 5, 2026 · After close | +4.7% |
| Q4 2025 | Feb 5, 2026 · After close | −4.3% |
| Q3 2025 | Nov 5, 2025 · After close | −11.5% |
| Q2 2025 | Aug 5, 2025 · After close | +5.8% |
| Q1 2025 | May 1, 2025 · After close | +33.7% |
| Q4 2024 | Feb 11, 2025 · After close | −3.2% |
| Q3 2024 | Nov 7, 2024 · After close | +3.4% |
| Q2 2024 | Aug 1, 2024 · After close | −3.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | +2.3% |
| Q4 2023 | Feb 14, 2024 · After close | +0.5% |
| Q3 2023 | Nov 9, 2023 · After close | −18.2% |
| Q2 2023 | Aug 2, 2023 · After close | −12.4% |
| Q1 2023 | May 3, 2023 · After close | −14.3% |
| Q4 2022 | Feb 14, 2023 · After close | +15.6% |
| Q3 2022 | Nov 3, 2022 · After close | +14.3% |
| Q2 2022 | Aug 3, 2022 · After close | +14.9% |
| Q1 2022 | May 4, 2022 · After close | −4.3% |
| Q4 2021 | Feb 15, 2022 · After close | +5.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2026 Earnings Presentation | Earnings | 31 slides | May 5, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 15 slides | Feb 5, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 24 slides | Jan 12, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 11 slides | 2026 |
| Q2 2026 Earnings Presentation | Earnings | 13 slides | 2026 |
| Q1 2025 Earnings Presentation | Earnings | 13 slides | May 1, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 17 slides | Feb 11, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 23 slides | Jan 14, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 15 slides | 2025 |
| Q3 2025 Earnings Presentation | Earnings | 13 slides | 2025 |
All 32 decks
Financings
| Raise | Date |
|---|---|
| 0% convertible senior notes due 2031 Made bigger: US$300M · J. Wood Capital Advisors LLC Dealers: J. Wood Capital Advisors LLC Use of proceeds: Capped call transactions, repurchase of $25 million of common stock, repayment of the OrbiMed Purchase Agreement, general corporate purposes and MRD initiatives | Jun 17, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$20.00 a share on Jun 26, 2019.
- Price
- US$20.00 a share
- Shares offered
- 15,000,000 shares of common stock
- Offering size
- US$300 million
- Underwriters' option
- Up to 2,250,000 more shares
- Underwriters
- Goldman Sachs & Co. LLC, J.P. Morgan, BofA Merrill Lynch, Cowen, Guggenheim Securities, William Blair, BTIG · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 29, 2019 |
| Filed publicly | May 30, 2019 |
| Amended 3 times | Newest Jun 26, 2019 |
| Shares registered with an exchange | Jun 26, 2019 |
| Declared effective by the SEC | Jun 26, 2019 |
| Final prospectus, with the price | Jun 27, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 27, 2019 |
| EFFECT · Notice that a registration is effective | Jun 26, 2019 |
| CERT · Exchange's certificate of listing | Jun 26, 2019 |
| S-1/A · Registration statement, amended | Jun 26, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 26, 2019 |
| CORRESP · Letter to the SEC | Jun 24, 2019 |
| CORRESP · Letter to the SEC | Jun 24, 2019 |
| S-1/A · Registration statement, amended | Jun 19, 2019 |
| CORRESP · Letter to the SEC | Jun 17, 2019 |
| S-1/A · Registration statement, amended | Jun 17, 2019 |
All 19 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jun 10, 2019 |
| CORRESP · Letter to the SEC | Jun 4, 2019 |
| CORRESP · Letter to the SEC | May 30, 2019 |
| S-1 · Registration statement | May 30, 2019 |
| UPLOAD · Letter from the SEC | May 23, 2019 |
| DRSLTR · Letter to the SEC with a draft | May 8, 2019 |
| DRS/A · Draft registration statement, amended | May 8, 2019 |
| UPLOAD · Letter from the SEC | Apr 25, 2019 |
| DRS · Draft registration statement | Mar 29, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 27, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 277.0M | 179.0M | 170.3M | 185.3M | 154.3M | 98.4M | 85.1M | 55.7M | 38.4M |
| Cost of revenue | 71.4M | 72.1M | 75.6M | 57.9M | 49.3M | 22.5M | 22.3M | 19.7M | 15.7M |
| Gross profit | 205.6M | 106.9M | 94.7M | 127.4M | 105.0M | 75.9M | 62.8M | 36.0M | 22.8M |
| Research and development | 93.8M | 103.0M | 122.1M | 141.8M | 142.3M | 116.1M | 70.7M | 39.2M | 32.0M |
| Selling, general and administrative | 72.7M | 72.8M | 83.9M | 88.5M | 74.5M | 49.5M | 30.3M | 20.4M | 15.9M |
| Operating income | -57.1M | -162.5M | -227.0M | -200.2M | -209.0M | -152.8M | -78.4M | -49.8M | -44.5M |
| Depreciation and amortization | 16.0M | 17.4M | 19.6M | 20.9M | 12.3M | 6.77M | 6.09M | 4.30M | 4.10M |
| EBITDA | -41.1M | -145.1M | -207.4M | -179.3M | -196.7M | -146.0M | -72.3M | -45.5M | -40.4M |
| Interest expense | 11.8M | 11.6M | 13.8M | 4.24M | 1.67M | 0 | 0 | 0 | 0 |
| Income before tax | -59.5M | -159.6M | -225.3M | -200.4M | -207.3M | -146.2M | -68.6M | -46.4M | -42.8M |
| Income tax | 0 | 0 | 0 | -57.9M | -1.69M | -6.59M | 0 | 3.31M | -804.0K |
| Net income | -59.5M | -159.5M | -225.3M | -200.2M | -207.3M | -146.2M | -68.6M | -46.4M | -42.8M |
| Earnings per share, basic | -0.39 | -1.08 | -1.56 | -1.40 | -1.48 | -1.11 | -1.01 | -3.67 | -3.50 |
| Earnings per share, diluted | -0.39 | -1.08 | -1.56 | -1.40 | -1.48 | -1.11 | -1.01 | -3.67 | -3.50 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 70.5M | 47.9M | 65.1M | 90.0M | 139.1M | 123.4M | 96.6M | 55.0M | 85.3M |
| Short-term investments | 156.5M | 174.4M | 281.3M | 408.2M | 214.0M | 564.8M | 480.3M | 110.0M | 106.8M |
| Receivables | 50.4M | 41.7M | 38.0M | 40.1M | 17.4M | 10.0M | 12.7M | 4.81M | 5.58M |
| Inventory | 9.82M | 8.44M | 14.4M | 14.5M | 19.3M | 14.1M | 9.07M | 7.84M | 4.79M |
| Current assets | 300.2M | 283.8M | 410.2M | 562.1M | 402.7M | 726.9M | 612.7M | 180.7M | 205.2M |
| Property, plant and equipment | 34.1M | 48.6M | 68.2M | 83.4M | 85.3M | 39.7M | 60.4M | 19.1M | 14.0M |
| Goodwill | 119.0M | 119.0M | 119.0M | 119.0M | 119.0M | 119.0M | 119.0M | 119.0M | 119.0M |
| Total assets | 512.7M | 539.4M | 661.1M | 856.6M | 923.3M | 1.12B | 912.3M | 332.7M | 362.5M |
| Accounts payable | 6.47M | 7.26M | 7.72M | 8.08M | 3.31M | 3.24M | 4.45M | 1.79M | 1.96M |
| Current liabilities | 89.9M | 98.1M | 88.0M | 109.8M | 113.8M | 105.2M | 78.3M | 22.8M | 21.0M |
| Long-term debt | 126.6M | 132.4M | 130.7M | 125.4M | 336.0K | 342.0K | |||
| Total debt | 131.2M | 133.3M | 130.7M | 125.4M | 111.7M | 107.9M | 36.6M | 561.2M | 561.7M |
| Total liabilities | 287.7M | 336.9M | 352.9M | 392.5M | 319.2M | 373.1M | 341.3M | 29.9M | 587.1M |
| Shareholders' equity | 218.8M | 202.7M | 308.4M | 464.2M | 604.0M | 743.3M | 571.0M | -258.1M | -224.6M |
| Shares outstanding | 153.8M | 147.8M | 145.1M | 143.1M | 141.4M | 137.6M | 125.2M | 12.8M | 139.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -46.0M | -95.2M | -156.3M | -183.9M | -192.7M | -149.7M | 205.4M | -32.3M | -34.9M |
| Capital spending | -2.96M | -3.66M | -10.7M | -16.3M | -61.7M | -18.8M | -11.2M | -6.30M | -2.42M |
| Free cash flow | -48.9M | -98.9M | -167.0M | -200.3M | -254.5M | -168.5M | 194.2M | -38.6M | -37.3M |
| Cash from investing | 38.0M | 77.8M | 129.6M | 2.90M | 181.2M | -117.0M | -481.7M | 736.0K | 36.4M |
| Cash from financing | 30.4M | 241.0K | 2.25M | 132.3M | 27.1M | 293.6M | 319.9M | 1.25M | 50.0M |
| Dividends paid | 0 | 0 | |||||||
| Share buybacks | 7.89M | 26.7M | 293.6M | 324.9M | 1.27M | 50.0M | |||
| Change in cash | 22.4M | -17.2M | -24.4M | -48.8M | 15.6M | 26.9M | 43.6M | -30.3M | 51.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 30, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 29, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 22, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 9, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 12, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 8-K · Current report | Dec 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Nov 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 9, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 6, 2025 | Big-stake notice | SEC |
This page holds 200 of 839 filings. Open Filings
Cap table
Built by 6ix from Adaptive Biotechnologies Corporation’s releases · as of Oct 30, 2026
- Common shares
- 161,876,694
- Fully diluted
- 161,876,694
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 161,876,694 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 161,876,694 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Hershberg Other companies: Danaher Corporation (Director · Since at least Nov 15, 2026); AtaiBeckley Inc. (Director · Since at least Jun 4, 2026); Hillevax Inc (President and CEO, Director · Since at least Apr 28, 2022); Recursion Pharmaceuticals, Inc. (Board Member · Since at least Apr 15, 2021); ARS Pharmaceuticals, Inc. (Director · Dec 3, 2020 – Jun 10, 2022 · Past); Fate Therapeutics, Inc. (Director · May 1, 2020 – Jun 6, 2023 · Past); NanoString Technologies Inc (Director · Mar 2, 2015 – Apr 18, 2022 · Past); Dendreon Corp (Sr. VP & Chief Medical Officer · Dec 31, 2005 – Jan 19, 2006 · Past) | Board Member · Since at least Jun 26, 2019 |
| Kevin T Conroy Other companies: Abbott Laboratories (Director · Since at least Apr 24, 2026); American Exceptionalism Acquisition Corp. A (Director · Since at least Sep 25, 2025); Align Technology, Inc. (Director · Since at least Dec 5, 2023); EXACT Sciences Corporation (President and CEO, Director · Since at least Mar 18, 2009); ARYA Sciences Acquisition Corp (Director · Oct 5, 2018 – Jul 1, 2020 · Past); Epizyme Inc (Director · Feb 6, 2017 – Aug 12, 2022 · Past) | Director · Jun 26, 2019 – Mar 6, 2023 · Past |
| Eric Dobmeier Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Janux Therapeutics, Inc. (Director · Since at least Jul 19, 2024); Structure Therapeutics, Inc. (Director · Since at least Feb 2, 2023); Aduro Biotech Inc (President, CEO, Director · Oct 5, 2020 – Aug 11, 2023 · Past); Atara Biotherapeutics, Inc. (Director · Jun 27, 2019 – Nov 10, 2023 · Past) | Director · Jun 26, 2019 – Feb 14, 2021 · Past |
| Chad Cohen Other companies: Grindr Inc. (Director · Since at least Jul 30, 2024); Vacasa Inc (Director · Dec 7, 2021 – Apr 30, 2025 · Past); Trupanion, Inc. (Director · Dec 7, 2015 – Mar 31, 2019 · Past); Zillow Group, Inc. (CFO & Treasurer · Mar 1, 2011 – Feb 17, 2015 · Past) | Chief Financial Officer · Jun 26, 2019 – Dec 22, 2021 · Past |
| David E Goel Other companies: Alumis Inc. (Director · Jun 27, 2024 – May 21, 2025 · Past); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Zentalis Pharmaceuticals, Inc. (Director · Apr 3, 2020 – Apr 3, 2020 · Past); Popular, Inc. (Director · Feb 12, 2012 – May 8, 2018 · Past) | Director · Jun 26, 2019 – Feb 15, 2021 · Past |
| Leslie Trigg Other companies: EXACT Sciences Corporation (Director · Since at least Apr 29, 2025); Outset Medical, Inc. (Chair and CEO · Since at least Aug 17, 2020); ARYA Sciences Acquisition IV Corp (Director · Feb 25, 2021 – Jul 31, 2024 · Past); Cardiovascular Systems Inc (Director · Aug 31, 2012 – Nov 18, 2016 · Past) | Director · Mar 17, 2021 – Mar 6, 2023 · Past |
| Peter Neupert Other companies: Fortrea Holdings Inc. (Director · Since at least Jun 29, 2023); Labcorp Holdings Inc. (Director · Since at least Jan 1, 2013); Nextgen Healthcare Inc (Director · Aug 15, 2013 – Aug 15, 2013 · Past); Aquantive Inc (Director · May 10, 2006 – May 10, 2006 · Past) | Board Member · Since at least Jun 26, 2019 |
| Chad Robins Other companies: CM Life Sciences III Inc. (Director · Apr 6, 2021 – Apr 6, 2021 · Past); Cerevel Therapeutics Holdings Inc (Director · Jun 4, 2020 – Jun 4, 2020 · Past) | Chief Executive Officer, Co-founder, Chairman of the Board · Since at least Jun 26, 2019 |
| Michelle Griffin Other companies: Acer Therapeutics Inc (Director · Mar 14, 2023 – Mar 14, 2023 · Past); Aduro Biotech Inc (Director · May 26, 2022 – Aug 11, 2023 · Past) | Board Member · Since at least Mar 6, 2023 |
| Harlan S Robins Other companies: CM Life Sciences III Inc. (Director · Apr 6, 2021 – Apr 6, 2021 · Past) | Chief Scientific Officer · Since at least Jun 26, 2019 |
All 34 people
| Person | Seat |
|---|---|
| Michael J Pellini Other companies: Singular Genomics Systems Inc (Director · May 29, 2024 – Feb 21, 2025 · Past) | Director · Mar 4, 2024 – Mar 4, 2025 · Past |
| ADAPTIVE INVESTORSKarina Calzadilla | Vice President, Investor Relations and FP& · Since at least Apr 15, 2026 |
| ADAPTIVE MEDIAErica Jones | Associate Corporate Communications · Since at least Apr 15, 2026 |
| Andris A Zoltners | Director · Jun 26, 2019 – Feb 13, 2020 · Past |
| Charles Sang | SVP, External Affairs · Jun 26, 2019 – Dec 11, 2020 · Past |
| Clarice McCauley | VP, Head of Legal · Since at least Nov 5, 2026 |
| Ed Moyle | Chief Information Security Officer · Dec 2, 2025 – Nov 5, 2026 · Past |
| Erica Jones | Associate Corporate Communications Director · Since at least Oct 14, 2026 |
| Francis Lo | Chief People Officer · Since at least Jun 26, 2019 |
| Jim Snook | Senior Vice President, Global Sales · Mar 5, 2026 – Nov 5, 2026 · Past |
| Jim Snook | Senior Vice President, Global Sales · Since Mar 5, 2026 · Appointed, no departure found |
| Julie Rubinstein | President & Chief Operating Officer · Since at least Jun 26, 2019 |
| Karina Calzadilla | Vice President, Investor Relations and FP&A · Since at least Oct 14, 2026 |
| Katey Owen | Board Member · Since at least Mar 17, 2021 |
| Kyle Piskel | Chief Financial Officer · Since at least Jun 26, 2019 |
| Lance Baldo | Chief Medical Officer · Jun 26, 2019 – Mar 8, 2022 · Past |
| Mary Pat Lancelotta | Senior Vice President, Global Market and Business Development · Since at least Jun 30, 2026 |
| Nancy Louise Hill | EVP, Operations & Program Mana · Jun 26, 2019 – Jan 19, 2021 · Past |
| Nitin Sood | Chief Commercial Officer, MRD · Aug 4, 2021 – Aug 7, 2023 · Past |
| R Mark Adams | Chief Operating Officer · Apr 6, 2020 – Apr 10, 2023 · Past |
| Sharon Benzeno | Chief Commercial Officer, Immune Medicine · Since at least Jun 26, 2019 |
| Stacy L Taylor | SVP and General Counsel · Jan 8, 2020 – Aug 22, 2024 · Past |
| Susan Bobulsky | Chief Commercial Officer, MRD · Since at least Aug 6, 2020 |
| Tycho Peterson | Chief Financial Officer · Jun 1, 2022 – Mar 4, 2024 · Past |
Log in to ask 6ix AI your own questions about Adaptive Biotechnologies Corporation.